Form 4: Alset International and Alset Inc. Reduce Stake in Impact Biomedical

Alset International and Alset Inc., entities related to director Chan Heng Fai Ambrose, have sold a significant number of Impact Biomedical shares.

Summary

• On March 31, 2025, Alset International Limited sold 300,000 shares of Impact Biomedical common stock at an average price of $1.028 per share.
• On April 1, 2025, Alset International Limited sold an additional 400,000 shares at an average price of $0.9816 per share.
• Also on April 1, 2025, Alset Inc. sold 650,000 shares at an average price of $1.447 per share.
• Further, on April 1, 2025, Alset Inc. sold 1,176,918 shares at an average price of $1.08 per share.
• Following these transactions, Mr. Chan may be deemed the beneficial owner of 2,041,248 shares through various entities.
• These entities include Global Biomedical Pte. Ltd. (453,286 shares), Alset International Limited (853,904 shares), and Alset Inc. (734,058 shares).

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant share sales by related parties, which could indicate a lack of confidence or a strategic shift away from the company.

Negatives

• Alset International and Alset Inc., entities related to a director, have reduced their stake in Impact Biomedical, which could be perceived negatively by investors.

Risks

• Continued selling pressure from major shareholders could negatively impact the stock price.
• The transactions were executed at varying prices, indicating potential volatility in the stock.

Industry Context

Sales of shares by significant shareholders are common and can be for a variety of reasons, including portfolio diversification or personal financial needs. However, they can sometimes signal a lack of confidence in the company's future prospects.

Comparison to Industry Standards

• It's difficult to compare these transactions to industry standards without knowing the specific reasons behind the sales.
• Generally, insider selling is monitored closely by investors, and significant sales can lead to increased scrutiny.

Related Party Transactions

• The document details sales of shares by Alset International Limited and Alset Inc., which are entities related to Chan Heng Fai Ambrose, a director of Impact Biomedical.

Stakeholder Impact

• Shareholders may react negatively to the news of significant share sales by related parties.
• The sales could create downward pressure on the stock price.

Key Dates

Keywords

Impact Biomedical, Alset International, Alset Inc., Chan Heng Fai Ambrose, share sale, beneficial ownership, Form 4, IBO